Response by Pérez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"

Circulation. 2023 Sep 26;148(13):1059-1060. doi: 10.1161/CIRCULATIONAHA.123.066276. Epub 2023 Sep 25.

Authors

Leopoldo Pérez de Isla¹, Adriana Saltijeral Cerezo², Pedro Mata³

Affiliations

¹ Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.).
² Cardiology Department, Hospital Vithas Aravaca, Madrid, Spain (A.S.C.).
³ Fundación Hipercolesterolemia Familiar, Madrid, Spain (P.M.).

PMID: 37747952
DOI: 10.1161/CIRCULATIONAHA.123.066276

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Coronary Artery Disease* / epidemiology
Humans
Hyperlipoproteinemia Type II* / complications
Hyperlipoproteinemia Type II* / diagnosis
Hyperlipoproteinemia Type II* / genetics

Substances

alirocumab
Antibodies, Monoclonal, Humanized